Human liver microsomes
Human liver microsomes are a preparation of subcellular fractions derived from human liver tissue. They contain metabolically active enzymes, primarily cytochrome P450 enzymes, that are involved in the biotransformation of various substances.
Lab products found in correlation
9 protocols using human liver microsomes
CYP3A4-Mediated Midazolam Metabolism
Optimized Metabolic Profiling Workflow
Microsomal and Plasma Samples Acquisition
Characterization of 5F-APINACA Metabolism
Analytical Characterization of Pyrrolizidine Alkaloids
Compound Characterization for Biological Evaluation
cDNA-expressed human P450 enzymes, uridine 5′-diphosphoglucuronosyltransferases (UGT), pooled human liver microsomes and pooled human liver cytosols were obtained from Corning Gentest (Woburn, MA, USA). Cryopreserved primary human hepatocytes from four donors XSM, HVN, DQB and OMA (
In vitro Metabolism of Novel Cannabinoids
Metabolic Stability Evaluation
of phase I metabolic stability, the compound (1 μM) was incubated
with 0.5 mg/mL pooled C57BL/6 mouse, Wistar rat liver microsomes (Xenotech,
Kansas City, USA), or human liver microsomes (Corning, New York, USA),
2 mM NADPH, and 10 mM MgCl2 at 37 °C for 120 min on
a microplate shaker (Eppendorf, Hamburg, Germany). The metabolic stability
of testosterone, verapamil, and ketoconazole was determined in parallel
to confirm the enzymatic activity of mouse/rat liver microsomes; for
human liver microsomes, testosterone, diclofenac, and propranolol
were used. Incubation was stopped after defined time points by precipitation
of aliquots of enzymes with 2 volumes of cold acetonitrile containing
an internal standard (15 nM diphenhydramine). Samples were stored
on ice until the end of the incubation, and precipitated protein was
removed by centrifugation (15 min, 4 °C, and 4000g). The concentration of the remaining test compound at the different
time points was analyzed by HPLC-MS/MS (TSQ Altis Plus, Thermo Fisher,
Dreieich, Germany) and used to determine the half-life (t1/2).
In Vitro Cytochrome P450 Inhibition Assay
were employed. Test compound (0.1, 0.25, 1, 2.5, 10, 25 μM)
was incubated with pooled human liver microsomes (0.25 mg/mL; Corning
Life Sciences), an appropriate isoform-specific probe substrate, and
NADPH (1 mM) at 37 °C for an isoform-specific incubation time.
The reactions were terminated by the addition of an aliquot of the
incubation into methanol. The samples were centrifuged at 2500 rpm
for 30 min at 4 °C, and aliquots of the supernatant were diluted
for LC–MS/MS analysis. The formation of isoform-specific metabolites
acetaminophen (CYP 1A2), hydroxybupropion (CYP 2B6), 6α-hydroxypaclitaxel
(CYP 2C8), 4 hydroxydiclofenac (CYP 2C9), 4-hydroxymephenytoin (CYP
2C19), dextrorphan (CYP 2D6), 1-hydroxymidazolam, and 6β-hydroxytestosterone
(CYP 3A4) were monitored. A decrease in the amount of metabolite formed
compared with vehicle control was used to calculate an IC50 value for each experimental condition.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!